{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:05:22Z","timestamp":1791813922384,"version":"4.3.4"},"reference-count":70,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.clml.2024.05.003","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T22:06:22Z","timestamp":1715724382000},"page":"665-693.e14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Clinical Management of Patients With Relapsed\/Refractory Multiple Myeloma Treated With Talquetamab"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0405-7480","authenticated-orcid":false,"given":"Ajai","family":"Chari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Rasche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing Christine","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Garfall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brea","family":"Lipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Campagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Masterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chalmer","family":"Tomlinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandi","family":"Hilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaszianne","family":"Tolbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Renaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Damiette","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Heuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels W.C.J.","family":"van de Donk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clml.2024.05.003_bib0001","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2024.05.003_bib0002","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"issue":"10301","key":"10.1016\/j.clml.2024.05.003_bib0003","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen\u2008\u00d7\u2008CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.clml.2024.05.003_bib0004","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2024.05.003_bib0005","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clml.2024.05.003_bib0006","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2024.05.003_bib0007","series-title":"American Society of Clinical Oncology (ASCO) Annual Meeting","article-title":"Pivotal phase 2 MonumenTAL-1 results of talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, for relapsed\/refractory multiple myeloma","author":"Schinke","year":"2023"},{"issue":"15","key":"10.1016\/j.clml.2024.05.003_bib0008","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood.2019003342","article-title":"A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma","volume":"135","author":"Pillarisetti","year":"2020","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.clml.2024.05.003_bib0009","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.clml.2024.05.003_bib0010","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.05.003_bib0011","series-title":"ASH Annual Meeting","author":"Bal","year":"2022"},{"issue":"2","key":"10.1016\/j.clml.2024.05.003_bib0012","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","article-title":"GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial","volume":"10","author":"Zhang","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2024.05.003_bib0013","series-title":"ASH Annual Meeting","article-title":"Forimtamig (RG6234), a GPRC5DxCD3 T-cell-engaging bispecific antibody, is highly active in patients with relapsed\/refractory multiple myeloma: updated intravenous and first subcutaneous results from a phase I dose-escalation study","author":"Carlo-Stella","year":"2022"},{"issue":"9","key":"10.1016\/j.clml.2024.05.003_bib0014","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1365-2362.2012.02679.x","article-title":"Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma","volume":"42","author":"Atamaniuk","year":"2012","journal-title":"Eur J Clin Invest"},{"issue":"9","key":"10.1016\/j.clml.2024.05.003_bib0015","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1158\/1535-7163.MCT-18-1216","article-title":"Anti-GPRC5D\/CD3 bispecific T-cell-redirecting antibody for the treatment of multiple myeloma","volume":"18","author":"Kodama","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"485","key":"10.1016\/j.clml.2024.05.003_bib0016","doi-asserted-by":"crossref","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"issue":"8","key":"10.1016\/j.clml.2024.05.003_bib0017","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2024.05.003_bib0018","series-title":"2023 American Society of Clinical Oncology (ASCO) Annual Meeting","article-title":"Analysis of infections and parameters of humoral immunity in patients with relapsed\/refractory multiple myeloma treated with talquetamab monotherapy in MonumenTAL-1","author":"Rodr\u00edguez-Otero","year":"2023"},{"key":"10.1016\/j.clml.2024.05.003_bib0019","unstructured":"United States Food and Drug Administration. TALVEY\u2122 (talquetamab-tgvs) [prescribing information]. Accessed: August 9, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761342s000lbl.pdf; 2023."},{"key":"10.1016\/j.clml.2024.05.003_bib0020","unstructured":"European Medicines Agency. TALVEY\u2122 (talquetamab). Summary of product characteristics. Accessed: January 3, 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/talvey-epar-product-information_en.pdf; 2023."},{"key":"10.1016\/j.clml.2024.05.003_bib0021","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pharmthera.2017.07.005","article-title":"Toxicity profiles of immunotherapy","volume":"181","author":"Cousin","year":"2018","journal-title":"Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.clml.2024.05.003_bib0022","doi-asserted-by":"crossref","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of immunotherapy-related toxicities, version 1.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"10.1016\/j.clml.2024.05.003_bib0023","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1158\/1535-7163.MCT-12-0087","article-title":"FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma","volume":"11","author":"Elkins","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1016\/j.clml.2024.05.003_bib0024","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clml.2024.05.003_bib0025","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41408-019-0178-8","article-title":"Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma","volume":"9","author":"Stewart","year":"2019","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.clml.2024.05.003_bib0026","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.3390\/cells8121632","article-title":"CD38 Expression by myeloma cells and its role in the context of bone marrow microenvironment: modulation by therapeutic agents","volume":"8","author":"Costa","year":"2019","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.clml.2024.05.003_bib0027","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1046\/j.0022-202X.2004.12628.x","article-title":"The RAIG family member, GPRC5D, is associated with hard-keratinized structures","volume":"122","author":"Inoue","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clml.2024.05.003_bib0028","series-title":"18th International Myeloma Society Annual Meeting","article-title":"Normal human tissue expression of G protein\u2013coupled receptor class C group 5 member D (GPRC5D), a promising novel target for multiple myeloma, is restricted to plasma cells and hard keratinized tissues","author":"Goldsmith","year":"2021"},{"issue":"4","key":"10.1016\/j.clml.2024.05.003_bib0029","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.job.2021.08.006","article-title":"The etiologies and considerations of dysgeusia: a review of literature","volume":"63","author":"Jafari","year":"2021","journal-title":"J Oral Biosci"},{"issue":"10","key":"10.1016\/j.clml.2024.05.003_bib0030","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.3390\/nu13103325","article-title":"Treatment-related dysgeusia in oral and oropharyngeal cancer: a comprehensive review","volume":"13","author":"Togni","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.clml.2024.05.003_bib0031","series-title":"American Society of Hematology (ASH) Annual Meeting","article-title":"Efficacy and safety of less frequent\/lower intensity dosing of talquetamab in patients with relapsed\/refractory multiple myeloma: results from the phase 1\/2 MonumenTAL-1 study","author":"Chari","year":"2023"},{"key":"10.1016\/j.clml.2024.05.003_bib0032","series-title":"2023 American Society of Clinical Oncology (ASCO) Annual Meeting","article-title":"Efficacy, safety, pharmacokinetic, and pharmacodynamic support for talquetamab QW and Q2W dosing in patients with relapsed\/refractory multiple myeloma: analyses from MonumenTAL-1","author":"Ma","year":"2023"},{"issue":"2","key":"10.1016\/j.clml.2024.05.003_bib0033","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/jtxs.12575","article-title":"Dry mouth diagnosis and saliva substitutes-a review from a textural perspective","volume":"52","author":"Hu","year":"2021","journal-title":"J Texture Stud"},{"issue":"3","key":"10.1016\/j.clml.2024.05.003_bib0034","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5005\/jcdp-9-3-72","article-title":"Saliva composition and functions: a comprehensive review","volume":"9","author":"de Almeida Pdel","year":"2008","journal-title":"J Contemp Dent Pract"},{"issue":"12","key":"10.1016\/j.clml.2024.05.003_bib0035","first-page":"3639","article-title":"Evaluating dysphagia","volume":"61","author":"Spieker","year":"2000","journal-title":"Am Fam Physician"},{"issue":"F1000 Faculty Rev","key":"10.1016\/j.clml.2024.05.003_bib0036","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.12688\/f1000research.18900.1","article-title":"Recent advances in dysphagia management","volume":"8","author":"Triggs","year":"2019","journal-title":"F1000Res"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2024.05.003_bib0037","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1182\/blood-2022-162555","article-title":"Health-related quality of life in patients with relapsed\/refractory multiple myeloma treated with talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody: patient-reported outcomes from MonumenTAL-1","volume":"140","author":"Touzeau","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2024.05.003_bib0038","doi-asserted-by":"crossref","first-page":"828","DOI":"10.36849\/jdd.7170","article-title":"Talquetamab-induced Grover's disease","volume":"22","author":"Kresch","year":"2023","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clml.2024.05.003_bib0039","series-title":"20th International Myeloma Society Annual Meeting","article-title":"Management considerations for dermatologic toxicities associated with talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma","author":"Purcell","year":"2023"},{"issue":"2","key":"10.1016\/j.clml.2024.05.003_bib0040","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000497232","article-title":"Prophylaxis and management of skin toxicities","volume":"14","author":"Salzmann","year":"2019","journal-title":"Breast Care (Basel)"},{"issue":"2","key":"10.1016\/j.clml.2024.05.003_bib0041","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2024.05.003_bib0042","doi-asserted-by":"crossref","first-page":"10073","DOI":"10.1182\/blood-2022-163733","article-title":"Infections and severe hypogammaglobulinemia in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"140","author":"Lancman","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2024.05.003_bib0043","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/bloodadvances.2021006178","article-title":"Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma","volume":"6","author":"Mohan","year":"2022","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2024.05.003_bib0044","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood-2019-127247","article-title":"Hypogammaglobulinemia and its implications in patients treated with daratumumab: a single institution experience","volume":"134","author":"Paul","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.05.003_bib0045","series-title":"EHA Annual Meeting","article-title":"RG6234, a novel GPRC5D T-Cell engaging bispecific antibody, induces rapid responses in patients with relapsed\/refractory multiple myeloma: preliminary results from a first-in-human trial","author":"Riley","year":"2022"},{"issue":"3","key":"10.1016\/j.clml.2024.05.003_bib0046","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2024.05.003_bib0047","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2024.05.003_bib0048","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/cncr.34756","article-title":"Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed\/refractory multiple myeloma","volume":"129","author":"Martin","year":"2023","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clml.2024.05.003_bib0049","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.05.003_bib0050","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies","volume":"40","author":"Xiao","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.clml.2024.05.003_bib0051","first-page":"625","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol BMT"},{"issue":"1","key":"10.1016\/j.clml.2024.05.003_bib0052","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.clml.2024.05.003_bib0053","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/14712598.2020.1729735","article-title":"Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy","volume":"20","author":"Chou","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.clml.2024.05.003_bib0054","unstructured":"Mayo Clinic. Mayo stratification for myeloma and risk-adapted therapy. Management of teclistamab cytokine release syndrome (CRS) and immune cell associated neurotoxicity syndrome (ICANS). Accessed: July 5, 2023. https:\/\/static1.squarespace.com\/static\/5b44f08ac258b493a25098a3\/t\/63f6c236a578cd1d5a097c65\/1677115959910\/mSMART+Teclistamab+guideline_V1_2023_rev.pdf; 2023."},{"key":"10.1016\/j.clml.2024.05.003_bib0055","unstructured":"Mayo Clinic. Mayo stratification for myeloma and risk-adapted therapy. Management of cytokine release syndrome (CRS) and immune cell associated neurotoxicity syndrome (ICANS). Accessed: July 5, 2023. https:\/\/static1.squarespace.com\/static\/5b44f08ac258b493a25098a3\/t\/6479eba26c01935cee7969f3\/1685711778896\/mSMART+CART+guideline_V1_2023.pdf; 2023."},{"key":"10.1016\/j.clml.2024.05.003_bib0056","doi-asserted-by":"crossref","first-page":"1110647","DOI":"10.3389\/fneur.2023.1110647","article-title":"A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome","volume":"14","author":"Butt","year":"2023","journal-title":"Front Neurol"},{"key":"10.1016\/j.clml.2024.05.003_bib0057","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3389\/fonc.2020.00885","article-title":"Recognizing and grading CAR T-cell toxicities: an advanced practitioner perspective","volume":"10","author":"Sievers","year":"2020","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.clml.2024.05.003_bib0058","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1097\/CAD.0000000000000814","article-title":"Tumour flare reaction in cancer treatments: a comprehensive literature review","volume":"30","author":"Taleb","year":"2019","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clml.2024.05.003_bib0059","doi-asserted-by":"crossref","first-page":"756583","DOI":"10.3389\/fimmu.2021.756583","article-title":"Tumor flare reaction in a classic Hodgkin lymphoma patient treated with brentuximab vedotin and tislelizumab: a case report","volume":"12","author":"Zhu","year":"2021","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.clml.2024.05.003_bib0060","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1097\/RLU.0000000000004588","article-title":"2-[18 F]FDG PET\/CT flare-up phenomena following T-cell engager bispecific antibody in multiple myeloma","volume":"48","author":"Jamet","year":"2023","journal-title":"Clin Nucl Med"},{"issue":"4","key":"10.1016\/j.clml.2024.05.003_bib0061","doi-asserted-by":"crossref","first-page":"655","DOI":"10.20892\/j.issn.2095-3941.2019.0144","article-title":"The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy","volume":"16","author":"Jia","year":"2019","journal-title":"Cancer Biol Med"},{"issue":"3","key":"10.1016\/j.clml.2024.05.003_bib0062","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/s41375-023-01824-0","article-title":"Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma","volume":"37","author":"Leipold","year":"2023","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.clml.2024.05.003_bib0063","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.clml.2024.05.003_bib0064","doi-asserted-by":"crossref","first-page":"7896","DOI":"10.1002\/cam4.3391","article-title":"Health-related quality of life of patients with multiple myeloma: a real-world study in China","volume":"9","author":"Li","year":"2020","journal-title":"Cancer Med"},{"issue":"Suppl. 7","key":"10.1016\/j.clml.2024.05.003_bib0065","doi-asserted-by":"crossref","first-page":"S834","DOI":"10.1016\/j.annonc.2022.07.764","article-title":"638P Burden of infection in patients with multiple myeloma and secondary immunodeficiencies: a retrospective cohort study","volume":"33","author":"Richter","year":"2022","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.clml.2024.05.003_bib0066","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.05.003_bib0067","series-title":"American Society of Clinical Oncology (ASCO) Annual Meeting","article-title":"First results from the RedirecTT-1 study with teclistamab + talquetamab simultaneously targeting BCMA and GPRC5D in patients with relapsed\/refractory multiple myeloma","author":"Cohen","year":"2023"},{"key":"10.1016\/j.clml.2024.05.003_bib0068","series-title":"American Society of Clinical Oncology (ASCO) Annual Meeting","article-title":"Talquetamab + daratumumab in patients with relapsed\/refractory multiple myeloma: updated TRIMM-2 results","author":"Dholaria","year":"2023"},{"key":"10.1016\/j.clml.2024.05.003_bib0069","series-title":"American Society of Hematology (ASH) Annual Meeting","article-title":"Talquetamab + pomalidomide in patients with relapsed\/refractory multiple myeloma: safety and preliminary efficacy results from the phase 1b MonumenTAL-2 study","author":"Matous","year":"2023"},{"key":"10.1016\/j.clml.2024.05.003_bib0070","series-title":"20th International Myeloma Society Annual Meeting","article-title":"Practical management of patients with relapsed\/refractory multiple myeloma receiving talquetamab, a GPRC5D\u00d7CD3 bispecific antibody: experience in MonumenTAL-1","author":"Catamero","year":"2023"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024001745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024001745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T11:10:43Z","timestamp":1729681843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024001745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":70,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2152265024001745"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.05.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Management of Patients With Relapsed\/Refractory Multiple Myeloma Treated With Talquetamab","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}